# Stalevo in Early Wearing-Off Patients

> **NCT00125567** · PHASE4 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 223 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** Stalevo (levodopa/carbidopa/entacapone)
- **DRUG:** Levodopa/carbidopa

## Key facts

- **NCT ID:** NCT00125567
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2009-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125567, "Stalevo in Early Wearing-Off Patients". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00125567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*